New FDA-Approved Nonhormone Option for the Treatment of Hot Flashes is the latest video in the North American Menopause Society’s Video Series-2023.

New FDA-Approved Nonhormone Option for the Treatment of Hot Flashes

What does the North American Menopause Society (NAMS) explain in their latest video, New FDA-Approved Nonhormone Option for the Treatment of Hot Flashes?

In Video Series-2023 the NAMS explain:

“In this latest video, New FDA-Approved Nonhormone Option for the Treatment of Hot Flashes Explained, Dr. Shapiro interviews Dr. Susan Reed, NAMS 2022-2023 President, Professor Emeritus in the Department of Obstetrics and Gynecology, and Adjunct Professor of Epidemiology at the University of Washington School of Medicine in Seattle, Washington”.

FDA Approval

What do the (United States) Food and Drug Administration (FDA) elaborate on about their approval of the drug Veozah (Fezolinetant) for the treatment of hot flashes caused by menopause?

In their news release FDA Approves Novel Drug To Treat Moderate To Severe Hot Flashes Caused By Menopause, dated 12 May 2023, the FDA elaborate on:

“Today, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause. It works by binding to and blocking the activities of the NK3 receptor, which plays a role in the brain’s regulation of body temperature”.

NK3 Inhibitors

What are NK3 inhibitors?

In the NAMS’s Video Series-2022: New Treatment Options for Menopause Symptoms Are Around the Corner NK3 Inhibitors are explained:

Health Topics A-Z

Where may I find Health Topics related to New FDA-Approved Nonhormone Option for Hot Flashes Video?

In Health Topics A-Z you may find:

Links

Where may I find Links related to New FDA-Approved Nonhormone Option for Hot Flashes Video?

Your Country may have Links similar to:

Last Updated: 01 June 2023 – Last Revised: 19 May 2023